Copyright © 1999 by the European Society of Cardiology.
Editorial
Different benefits, different risks, equal cost
Centro Cuore Columbus, Ospedale San Raffaele, Milan, Italy
References
- Lancet. 1997;349:14291435[CrossRef][Web of Science][Medline]
- Hamm CW, Heeschen C, Goldmann B. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med. 1999;340:16231629
[Abstract/Free Full Text] - Van den Brand M, Laarman GJ, Steg PJ. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. Eur Heart J. 1999;20:15721578
[Abstract/Free Full Text] - N Engl J Med. 1994;330:956961
[Abstract/Free Full Text] - N Engl J Med. 1997;336:16891696
[Abstract/Free Full Text] - Ellis SG, Lincoff MA, Miller D. Reduction of complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. J Am Coll Cardiol. 1998;32:16191623
[Abstract/Free Full Text] - Colombo A, Maiello L, Itoh A. Coronary stenting of bifurcation lesion: immediate and follow-up results. J Am Coll Cardiol. 1996;27:227A
- Pan M, de Lenzo JS, Medina A. Simple and complex stent strategies for bifurcated coronary arterial stenosis involving the side branch origin. Am J Cardiol. 1999;83:13201325[CrossRef][Web of Science][Medline]
- Lancet. 1998;352:8792[Web of Science][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||